Such is the case of the inducible hypoxia factor HIF-1, which by reporter gene assays, chromatin immunoprecipitation, and EMSA was shown that it is capable of regulating the expression of BCL-xL by binding to responding elements in the BCL-xL promoter in prostate cancer cells [52]. Here, BCL2L1 is linked to prostate carcinoma.